Xuemei Fang
Papers
1
Total Citations
4
H-Index
1
About
Xuemei Fang is a leading clinical researcher in head and neck oncology, with a focused expertise in human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC). Her most impactful work pioneers neoadjuvant immunotherapy combined with chemotherapy to enable less radical surgical interventions. In a landmark single-arm, phase 2 trial, Dr. Fang demonstrated that two cycles of sintilimab, cisplatin, and nab-paclitaxel, followed by transoral robotic surgery (TORS), can achieve major pathological responses in patients with resectable, HPV-positive OPSCC. This approach aims to de-escalate treatment intensity while preserving oncologic outcomes, potentially reducing long-term toxicity from traditional chemoradiation. Although her most cited paper currently holds 4 citations, its recent publication in 2025 signals growing recognition of her contributions to precision surgery and immunotherapy integration. Dr. Fang’s work sits at the critical intersection of immunotherapy, surgical oncology, and virology-driven cancer care, offering a promising paradigm for organ preservation and functional recovery. Her research is particularly valuable for students and clinicians interested in de-escalation strategies, transoral surgical techniques, and the evolving role of checkpoint inhibitors in HPV-mediated malignancies.
Research Focus
Key Achievements
Top Papers
- 1